FOLH1 and neoplasm: One 64Cu-DOTHA2-PSMA treated mouse and one 177Lu-PSMA-617 treated mouse were retrospectively rejected from survival experiments after injection, as they should not have been included in the protocol because of an oversized tumor at the beginning of treatment.